OR WAIT null SECS
Geniko Nosokomeio Thessalonikis “Papageorgiou” brings its patients and physicians quicker access to innovative medical treatments by joining Clinerion’s Patient Network Explorer platform.
Based in the city of Thessaloniki, Greece, “Papageorgiou” General Hospital has 746 beds and specializes in research on multiple sclerosis, dementia, pemphigus, plaque psoriasis, chronic kidney disease (anemia, diabetes mellitus type 2, bone metabolism in dialysis), ischemic heart disease and acute coronary syndromes, ventricular arrhythmias/dysfunction, prevention of sudden cardiac death, atrial fibrillation, heart failure, in various cancer areas (incl. breast cancer, non-small-cell lung cancer, urothelial/bladder cancer, gastric cancer, renal cell cancer, ovarian cancer, prostate cancer), bladder disorders (incl. neurogenic bladder disorder, overactive bladder disorder,) urinary tract infections, erectile dysfunction, pathogenesis, vascular function and complications of cardiovascular risk factors and diseases such as essential hypertension, diabetes mellitus, hyperlipidemia, stroke etc. The hospital runs approximately 62 new clinical trials per year.
With the hospital joining Patient Network Explorer, patients at Geniko Nosokomeio Thessalonikis “Papageorgiou” will be matched to clinical trials being run by international pharmaceutical companies on innovative medical interventions, as well as those being run by the hospital’s own academic researchers. This gives patients and physicians at the hospital access to treatment options and supports the acceleration of the introduction of these treatments into the market.
“With our experience, expertise and infrastructure, our hospital is in a strong position to support international trials,” says Vasileios Papas, Chairman of the Board of the hospital. “We are proud to have been recognized for infrastructure quality for implementation of clinical trials, fast-track administrative procedures, and a friendly organizational environment by the SFEE (the Hellenic Association of Pharmaceutical Companies).”
“Clinerion is thrilled to further expand our coverage of the Greek patient population through the Papageorgiou General Hospital,” says Ian Rentsch, CEO of Clinerion. “We already cover patients in Athens, and this will greatly benefit patients in the area of Thessaloniki, Greece’s second largest cosmopolitan area, in getting earlier access to medical innovations.”